AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01585285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIMA to SVG Bridge Technique
Description: This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
Study NCT00412243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m\^2 Daily for 3 Days
Study NCT00412243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Beginning dose 200 mg/m\^2 every 12 hours for 3 days
Study NCT01944540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized ESD with snaring
Study NCT01944540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Study NCT03223116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency delivery
Description: Radiofrequency to the gastroesophageal junction
Study NCT00763919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Description: The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
Study NCT00763919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance abuse module
Description: The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
Study NCT00763919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved communication/rapport with provider module
Description: The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
Study NCT00763919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication routines management module
Description: The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
Study NCT02659176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair with PIS
Description: Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
Study NCT02659176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair without PIS
Description: Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
Study NCT03671499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory based text messages
Description: Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
Study NCT02574910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
Study NCT01585285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
Study NCT04553328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Us guided nerve blocks
Description: The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
Study NCT00870012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lepicol probiotic & prebiotic formula
Description: NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
Study NCT00870012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple lifestyle advice
Description: NAFLD patients treated with lifestyle advice.
Study NCT00870012 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simple lifestyle advice
Description: NAFLD patients treated with lifestyle advice.
Study NCT03499834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Killer Cells (IKC)
Description: Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
Study NCT01402713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1107
Description: GC1107-T5.0: low dose, GC1107-T7.5: high dose
Study NCT03413618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Study NCT03413618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Study NCT01402713 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TD_PUR INJ / SK Td vaccine
Description: step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
Study NCT02982421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group art therapy
Description: Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
Study NCT02982421 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
Study NCT04270968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extra-corporeal shock wave therapy
Description: Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.
Study NCT04270968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical none steroidal anti-inflammatory drug
Description: participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
Study NCT04417335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.
Study NCT04417335 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study NCT04267835 — intervention group
Intervention type: PROCEDURE
Intervention: MIDCAB
Description: Surgery: MIDCAB
Study NCT04267835 — intervention group
Intervention type: PROCEDURE
Intervention: thoracotomy OPCABG
Description: Surgery: thoracotomy OPCABG
Study NCT03918915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 1
Description: Sterile topical ophthalmic solution
Study NCT03918915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD-101 Dose 2
Description: Sterile topical ophthalmic solution
Study NCT05060406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY06006
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
Study NCT05060406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY06006
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
Study NCT03639194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-011
Description: Intravenous
Study NCT03413618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: 600 mg q.d. for 12 month
Study NCT03918915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYD-101 Dose 2
Description: Sterile topical ophthalmic solution
Study NCT03918915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Sterile topical ophthalmic solution without active ingredient
Study NCT03413618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compression stockings
Description: above knee stocking for 12 month
Study NCT03639194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous
Study NCT03413618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression stockings
Description: above knee stocking for 12 month
Study NCT00934661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Epidural Morphine (EREM)
Description: A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
Study NCT00934661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
Study NCT01334281 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
Study NCT01334281 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
Study NCT01321086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: 9 sessions of MI from baseline to six months
Study NCT01321086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: 9 sessions of PACE delivered from baseline to six months
Study NCT02035891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colchicine 0.5mg/d
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Study NCT02035891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 0.5mg/d
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Study NCT05098678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: 120 mg each tablet containing 30 mg elemental zinc
Study NCT05098678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose): 1 tablet (120 mg each)
Study NCT03918915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Sterile topical ophthalmic solution without active ingredient
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage 500Mg Tablet
Description: 0.5g three times daily
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose Tablets
Description: 50mg three times daily
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin tablet
Description: 100mg once daily
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Tablet
Description: 10mg once daily
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Tablets
Description: 30mg once daily
Study NCT04287387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets
Description: 2mg once daily
Study NCT03355066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM08502
Description: SM08502 tablets to be administered orally.
Study NCT04067258 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EDI-OCT
Description: EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged.
Study NCT02115763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02115763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04165850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Ciprofloxacin/Celecoxib
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
Study NCT00749723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
Study NCT01749722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviAid™ G-Eye procedure
Description: NaviAid™ G-Eye procedure
Study NCT02588924 — intervention group
Intervention type: OTHER
Intervention: Second University of Naples
Description: enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
Study NCT02588924 — intervention group
Intervention type: OTHER
Intervention: Neuromed IRCCS
Description: enrollment of patients with Parkinson's disease; collection of blood samples;
Study NCT01515969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride
Description: Given PO
Study NCT01515969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib lactate
Description: Given PO
Study NCT04685304 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Testing
Description: Genetic results will be reported for CYP2D6, CYP2C19, CYP2C9, CYP2B6, CYP3A4, CYP3A5, SLCO1B1, TPMT, and VKORC1.
Study NCT04685304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Consultation Note
Description: Recommendations will be based on phenotypes translated from genetic data in accordance with CPIC guidelines. Drug interactions will be incorporated into phenotype assignments when appropriate.
Study NCT04685304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed pharmacogenetic testing
Description: Pharmacogenetic testing and a pharmacist consultation note will be provided to participants provided to the standard care arm once 3 months have passed since their baseline visit.
Study NCT03179085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Kidney Care
Description: All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
Study NCT03179085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Kidney Care
Description: All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
Study NCT01231581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Study NCT01231581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
Study NCT01231581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
Study NCT01231581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
Study NCT03508856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Picato®) 0.015% gel
Study NCT01497210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EASH dressing
Description: Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
Study NCT01236755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-vision glasses
Description: Daily wear of glasses to correct vision in the first seven months of the study
Study NCT01236755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ortho-k lenses
Description: Nightly wear of lenses to correct vision in day time in the second seven months of the study
Study NCT01080313 — intervention group
Intervention type: OTHER
Intervention: Therapy for head and neck cancer
Description: radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
Study NCT01176292 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rotating Platform High-Flex Cruciate Substituting TKA
Study NCT01176292 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rotating Platform Cruciate Substituting TKA
Study NCT03093675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELELAP ALF-X Robotic Surgical System
Description: The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
Study NCT00838266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)
Description: Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
Study NCT00838266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mouthrinse containing non-active component
Description: Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropin
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone vaginal insert
Description: 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal insert
Description: 100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Study NCT00805935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta
Description: 225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.